SLC13A2
Solute carrier family 13 member 2
Also known as: NaDC-1, S13A2_HUMAN
Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene
Protein identityUniProt · HPA
- UniProt accession
- Q13183
- Gene
- SLC13A2
- Ensembl
- ENSG00000007216
- Chromosome
- 17
- Canonical length
- 592 aa
- Protein class
- Metabolic proteins, Predicted membrane proteins, Transporters
OverviewNCBI Gene
The protein encoded by this gene is a sodium-coupled citrate transporter that is regulated by the chaperone activity of cyclophilin b. The encoded protein may play a role in the formation of kidney stones. [provided by RefSeq, Oct 2016]
Canonical amino-acid sequenceUniProt
592 residues, UniProt reviewed canonical sequence.
>Q13183|SLC13A2
1 MATCWQALWA YRSYLIVFFV PILLLPLPIL VPSKEAYCAY AIILMALFWC TEALPLAVTA
61 LFPLILFPMM GIVDASEVAV EYLKDSNLLF FGGLLVAIAV EHWNLHKRIA LRVLLIVGVR
121 PAPLILGFML VTAFLSMWIS NTATSAMMVP IAHAVLDQLH SSQASSNVEE GSNNPTFELQ
181 EPSPQKEVTK LDNGQALPVT SASSEGRAHL SQKHLHLTQC MSLCVCYSAS IGGIATLTGT
241 APNLVLQGQI NSLFPQNGNV VNFASWFSFA FPTMVILLLL AWLWLQILFL GFNFRKNFGI
301 GEKMQEQQQA AYCVIQTEHR LLGPMTFAEK AISILFVILV LLWFTREPGF FLGWGNLAFP
361 NAKGESMVSD GTVAIFIGII MFIIPSKFPG LTQDPENPGK LKAPLGLLDW KTVNQKMPWN
421 IVLLLGGGYA LAKGSERSGL SEWLGNKLTP LQSVPAPAIA IILSLLVATF TECTSNVATT
481 TIFLPILASM AQAICLHPLY VMLPCTLATS LAFMLPVATP PNAIVFSFGD LKVLDMARAG
541 FLLNIIGVLI IALAINSWGI PLFSLHSFPS WAQSNTTAQC LPSLANTTTP SPLocalizationUniProt · AlphaFold · HPA
Whether an antibody against SLC13A2 can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.
- Antibody reachability
- Cell surface
- Secreted
- No
- Transmembrane segments
- 12
- Mean surface accessibility (rSASA)
- 0.27
- Highest tissue expression
- 122 nTPM
Expression across tissuesHPA
Tissue
- duodenum: 122 nTPM
- small intestine: 100 nTPM
- salivary gland: 45 nTPM
- kidney: 40 nTPM
- seminal vesicle: 12 nTPM
- gallbladder: 8.5 nTPM
Single-cell type
- enterocytes: 346 nCPM
- lacrimal acinar cells: 111 nCPM
- proximal tubule cells: 49 nCPM
- breast secretory cells: 33 nCPM
- enteric stem cells: 29 nCPM
- enteric transient amplifying cells: 28 nCPM
Immune cell
- basophil: 0 nTPM
- classical monocyte: 0 nTPM
- eosinophil: 0 nTPM
- gdT-cell: 0 nTPM
- intermediate monocyte: 0 nTPM
- MAIT T-cell: 0 nTPM
Brain region
- choroid plexus: 1.6 nTPM
- cerebral cortex: 0.1 nTPM
- hippocampal formation: 0.1 nTPM
- amygdala: 0 nTPM
- basal ganglia: 0 nTPM
- cerebellum: 0 nTPM
Genetic constraint and essentialitygnomAD · DepMap
Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.
- gnomAD LOEUF (loss-of-function intolerance)
- 1.15
- gnomAD pLI
- 0
- gnomAD missense Z
- 0.96
- DepMap mean gene effect
- -0.22
- DepMap dependency class
- selective
Cancer expressionTCGA
Across TCGA tumor cohorts, this protein is over-expressed in roughly 3% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).
OntologyGO
Biological processes
- alpha-ketoglutarate transport
- cellular response to lithium ion
- fumarate transport
- succinate transmembrane transport
Molecular functions
- alpha-ketoglutarate transmembrane transporter activity
- sodium:dicarboxylate symporter activity
- succinate transmembrane transporter activity
- fumarate transmembrane transporter activity
- low-affinity sodium:dicarboxylate symporter activity
Cellular components
Protein domainsUniProt · Pfam · InterPro
KeywordsUniProt
Antibody and autoantibody relevanceSeroatlas analysis
Seroatlas reads SLC13A2 as an antibody target. Whether an autoantibody or antibody against SLC13A2 could matter depends on whether native SLC13A2 is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.
SLC13A2 is annotated at the cell surface, where native SLC13A2 is exposed to circulating antibodies and is a prime autoantibody target that could block, deplete, or overstimulate it.
Annotation status
The present source text does not explicitly label SLC13A2 as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.
Loading the interactive Seroatlas protein explorer...